Shufro Rose & Co’s Ovid Therapeutics OVID Stock Holding History

Shufro Rose & Co’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,000	Closed	-$75K	–	299
2020 Q1	$75K	Buy	+25,000	New	+$84.2K	0.01%	273

Other funds holding OVID

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shufro Rose & Co's OVID Position: Q2 2020 in Review

Shufro Rose & Co sold out of Ovid Therapeutics (OVID) in Q2 2020, closing a stake of 25,000 shares — an estimated $75K sold.

Shufro Rose & Co first reported a position in OVID in Q1 2020 and held it in 1 quarter. The position peaked at $75K in Q1 2020. 79 funds tracked by Wall St. Rank hold OVID as of Q2 2020.

Shufro Rose & Co reported no remaining Ovid Therapeutics position as of Q2 2020 after selling out during the quarter.
Shufro Rose & Co sold 25,000 Ovid Therapeutics shares in Q2 2020, an estimated $75K.
Shufro Rose & Co first reported a position in Ovid Therapeutics in Q1 2020 and held it in 1 quarter.
Shufro Rose & Co's Ovid Therapeutics position peaked at $75K in Q1 2020.
79 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2020.

Based on Shufro Rose & Co's 13F filing for Q2 2020, filed 6 Aug 2020.